Ensysce Biosciences CEO Dr Lynn Kirkpatrick says she’s encouraged by position bioequivalence study data of the company’s novel Trypsin-Activated Abuse-Protected (TAAP) drug, PF614.
Kirkpatrick told Proactive that the study follows the successful completion of the multi-ascending twice-daily dosing study of PF614 and compared the release of oxycodone from PF614 versus OxyContin administered to subjects in both fasted and fed states.
She also discussed the company’s Multi-Pill Abuse Resistance (MPAR) platform and outlined the steps to commercialization of safer prescription drugs.
